1. BCG priming followed by a novel interleukin combination activates Natural Killer cells to selectively proliferate and become anti-tumour long-lived effectors.
- Author
-
Felgueres MJ, Esteso G, García-Jiménez ÁF, Dopazo A, Aguiló N, Mestre-Durán C, Martínez-Piñeiro L, Pérez-Martínez A, Reyburn HT, and Valés-Gómez M
- Subjects
- Humans, Neoplasms immunology, Neoplasms drug therapy, BCG Vaccine immunology, BCG Vaccine administration & dosage, Mycobacterium bovis immunology, Lymphocyte Activation drug effects, NK Cell Lectin-Like Receptor Subfamily K metabolism, Interleukins metabolism, CD56 Antigen metabolism, NK Cell Lectin-Like Receptor Subfamily C metabolism, Killer Cells, Natural immunology, Killer Cells, Natural drug effects, Cell Proliferation drug effects
- Abstract
The short-lived nature and heterogeneity of Natural Killer (NK) cells limit the development of NK cell-based therapies, despite their proven safety and efficacy against cancer. Here, we describe the biological basis, detailed phenotype and function of long-lived anti-tumour human NK cells (CD56
high CD16+ ), obtained without cell sorting or feeder cells, after priming of peripheral blood cells with Bacillus Calmette-Guérin (BCG). Further, we demonstrate that survival doses of a cytokine combination, excluding IL18, administered just weekly to BCG-primed NK cells avoids innate lymphocyte exhaustion and leads to specific long-term proliferation of innate cells that exert potent cytotoxic function against a broad range of solid tumours, mainly through NKG2D. Strikingly, a NKG2C+ CD57- FcεRIγ+ NK cell population expands after BCG and cytokine stimulation, independently of HCMV serology. This strategy was exploited to rescue anti-tumour NK cells even from the suppressor environment of cancer patients' bone marrow, demonstrating that BCG confers durable anti-tumour features to NK cells., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF